Ruge T, et al. - In this sub-study of the CLARICOR-trial (a randomized, placebo-controlled trial assessing the efficacy of 14-day treatment with clarithromycin in stable coronary heart disease patients), researchers examined links between serum endostatin upon entry (randomization) and the composite outcome and its parts during 10-year follow-up. The discovery sample was the placebo group (1,204 events, n = 1,998) and the replication sample the clarithromycin-treated group (1220 events, n=1979). An increased risk of the composite outcome was observed in relation to higher serum endostatin in the discovery sample, but, this link was slightly weaker and not statistically significant in the replication sample in Cox regression models adjusting for cardiovascular risk factors, glomerular filtration rate, and current pharmacological treatment. Overall, elevated serum endostatin might be related to cardiovascular events in patients with stable coronary heart disease.